These findings contrast with a meta-analysis of 11 articles involving 3060 GC patients, which reported that SOX9 expression was associated with TNM staging, tumor invasion depth, and poor overall survival, but not with age, sex, differentiation, or lymph node metastasis [14]. The gene discussed is SOX9; the disease is metastatic malignant neoplasm in the lymph nodes.